# A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection

> **NCT04637828** · PHASE2 · UNKNOWN · sponsor: **Genoscience Pharma** · enrollment: 178 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** GNS561

## Key facts

- **NCT ID:** NCT04637828
- **Lead sponsor:** Genoscience Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-18
- **Primary completion:** 2021-07-30
- **Final completion:** 2021-12-30
- **Target enrollment:** 178 (ESTIMATED)
- **Last updated:** 2021-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04637828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04637828, "A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04637828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*